Schwangerschafts protein 1 (SP1) adds little to the age-related detection of fetal Down syndrome in the first trimester of pregnancy

Kornman, Louise; Morssink, L. P.; Hoor, Klaske A. ten; Wolf, B. T. H. M. De; Kloosterman, M. D.; Beekhuis, J. R.; Mantingh, A.

doi:10.1002/(sici)1097-0223(199810)18:10<1086::aid-pd393>3.0.co;2-8

Cited by 5 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These were 65 of the 77 cases and 318 of the 383 controls used in previous analyses of different serum markers (Wald et al, 1996) (those with serum samples still available) plus some more recent samples. None of the samples had been used in previous SP1 studies; we excluded five cases and their corresponding controls from Groningen, Netherlands, because they were the subject of a previous report (Kornman et al, 1998). The SP1 assays were performed at the Statum Serum Institut in Copenhagen, without knowledge of whether each sample came from a case or control.…”

Section: Methodsmentioning

confidence: 99%

“…During the first trimester of pregnancy (8 to 14 weeks' gestational age), the maternal serum concentration of pregnancy-specific beta-1-glycoprotein (otherwise known as Schwangerschafts protein 1, SP1) tends to be lower in pregnancies associated with Down syndrome than in unaffected pregnancies. While several previous studies have found lower values in Down syndrome pregnancies (Brizot et al, 1995;Brock et al, 1990;Kornman et al, 1998;Qin et al, 1997;Macintosh et al, 1993;Aitken et al, 1993;Brambati et al, 1991), the size of the association is uncertain: estimates have varied considerably between 0.27 multiples of the median (MOM) and 0.89 MOM. The variation may be partly explained by the small size of many of the studies.…”

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

SP1 in pregnancies with Down syndrome in the first trimester of pregnancy

Wald¹,

Watt²,

Norgaard‐Pedersen³

et al. 1999

Prenat. Diagn.

View full text Add to dashboard Cite

We conducted a study to determine the value of serum pregnancy-specific beta-1-glycoprotein (Schwangerschafts protein 1, SP1) as an antenatal screening test for Down syndrome in the first trimester. Serum samples collected from women at 8 to 14 weeks of pregnancy, immediately prior to having a chorionic villus sampling procedure on account of advanced maternal age, were retrieved from 96 women with Down syndrome pregnancies (cases) and from 480 women with unaffected pregnancies (controls). Cases and controls were ascertained at 21 obstetric centres in nine countries. Each case was matched with five controls for maternal age (same five-year age groups), duration of storage of the serum sample (same calendar year) and gestational age (usually the same week of pregnancy). The levels of SP1 were lower in pregnancies associated with Down syndrome: the median level was 0.86 multiples of the median level in the controls (95 per cent confidence interval 0.76 to 0.97). This difference, though statistically significant, was not large enough for SP1 to be a useful marker in screening, at least from 10 weeks onwards where most of our data lie.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 95%

SP1 in pregnancies with Down syndrome in the first trimester of pregnancy

Wald¹,

Watt²,

Norgaard‐Pedersen³

et al. 1999

Prenat. Diagn.

View full text Add to dashboard Cite

show abstract

“…Besides PAPP-A, more potential markers were studied (e.g. SP1 (Kornman et al, 1998) andCA125 (Van Lith et al, 1993)), but none of those turned out to be worth adding to the screening test. The search for DS screening markers was not limited to biochemical markers; an enlarged nuchal translucency (NT) on a first trimester ultrasound scan also turned out to be predictive for DS (Nicolaides et al, 1992, Pandya et al, 1994.…”

Section: Prenatal Screening For Down Syndromementioning

confidence: 99%

Innovations in Down Syndrome Screening

Koster¹,

Vries²,

Visser³

et al. 2011

Prenatal Diagnosis and Screening for Down Syndrome

View full text Add to dashboard Cite

SP1 in pregnancies with Down syndrome in the first trimester of pregnancy

Wald¹,

Watt²,

Nørgaard‐Pedersen

et al. 1999

Prenat. Diagn.

View full text Add to dashboard Cite

We conducted a study to determine the value of serum pregnancy‐specific beta‐1‐glycoprotein (Schwangerschafts protein 1, SP1) as an antenatal screening test for Down syndrome in the first trimester. Serum samples collected from women at 8 to 14 weeks of pregnancy, immediately prior to having a chorionic villus sampling procedure on account of advanced maternal age, were retrieved from 96 women with Down syndrome pregnancies (cases) and from 480 women with unaffected pregnancies (controls). Cases and controls were ascertained at 21 obstetric centres in nine countries. Each case was matched with five controls for maternal age (same five‐year age groups), duration of storage of the serum sample (same calendar year) and gestational age (usually the same week of pregnancy). The levels of SP1 were lower in pregnancies associated with Down syndrome: the median level was 0.86 multiples of the median level in the controls (95 per cent confidence interval 0.76 to 0.97). This difference, though statistically significant, was not large enough for SP1 to be a useful marker in screening, at least from 10 weeks onwards where most of our data lie. Copyright © 1999 John Wiley & Sons, Ltd.

show abstract

Schwangerschafts protein 1 (SP1) adds little to the age-related detection of fetal Down syndrome in the first trimester of pregnancy

Cited by 5 publications

References 13 publications

SP1 in pregnancies with Down syndrome in the first trimester of pregnancy

SP1 in pregnancies with Down syndrome in the first trimester of pregnancy

Innovations in Down Syndrome Screening

SP1 in pregnancies with Down syndrome in the first trimester of pregnancy

Contact Info

Product

Resources

About